CRLF2 and B-cell acute lymphoblastic leukemia: This diagnostic blind spot carries significant clinical implications, as IGH::CRLF2 rearrangements are enriched in Ph-like B-cell acute lymphoblastic leukemia (Ph-like B-ALL) and have been associated with high-risk disease features and poor clinical outcomes [6].